

Toxicological Safety Evaluations of Extractables & Leachables

Trainer



Kevin Breesch, MSc Manager Toxicology Nelsonlabs Europe

- Master in Biochemistry
- Preclinical Toxicology program Manager (2010-2017)
- Manager Toxicological safety assessments (2017-current)

Participant Introductions



1. Name

2. Company

3. Department

4. Learning Expectations



Training Course Outline

- Basic Toxicological Principles
- Key Toxicological Endpoints
- Applicable Safety Limits and Thresholds
- General Impurity Qualification
- Best Practice Conclusions



Learning Objectives

PDA Parenteral Drug Association

- Understanding the basic concepts in Toxicology
 - Important toxicological endpoints
 - Relevant toxicological studies and data to look for
- Application of relevant safety thresholds
 - TTC, SCT, AET, PDE,...
- Safety evaluation strategies for Extractables and Leachables
 - Literature search
 - QSAR models predictive toxicology
 - Generic threshold or can we derive a PDE?

Training Course Outline

- Basic Toxicological Principles
- Key Toxicological Endpoints
- Applicable Safety Limits and Thresholds
- General Impurity Qualification
- Best Practice Conclusions



THE DOSE-RESPONSE





Hypothesis:

"All compounds are toxic, but below a certain dose – they are NOT"

→ Concept of <u>NOAEL</u>

No Observed Adverse Effect Level

"The Dose Makes the Poison" Paracelsus, Swiss MD (1492-1541)

THE DOSE-RESPONSE RELATIONSHIP




RESPONSE:


- Efficacy API
- Toxicity Impurity












THE DOSE-RESPONSE RELATIONSHIP



EXAMPLE: ACCUTE SYSTEMIC TOXICITY



Training Course Outline


- Basic Toxicological Principles
- Key Toxicological Endpoints
- Applicable Safety Limits and Thresholds
- General Impurity Qualification
- Best Practice Conclusions



KEY ENDPOINTS



Toxicological endpoints to be considered (non – limitative):



KEY ENDPOINTS: SYSTEMIC TOXICITYITY



<u>Acute systemic toxicity</u> testing is the estimation of the human hazard potential of a substance by determining its systemic toxicity in a test system (currently animals) following an acute exposure.

- <u>Single dose</u> exposure (<24 hrs)
- Major toxicity 1 or 2 organs
- LD50 value

<u>Systemic toxicity</u> testing is the estimation of the human hazard potential of a substance by determining its systemic toxicity in a test system (currently animals) following an <u>repeat</u> exposure.

- Daily exposure (negative control; LOW-; MID- and HIGH- dose group)
- Low dose ~ NOEL or NOAEL or LOAEL

OECD Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents




Genotoxicity is a broad term referring to genetic damage. This may be at a *DNA level* i.e. mutagenicity, or at a *chromosomal level* e.g. Clastogenicity / Aneugenicity.

This term has been **replaced**, in the context of **ICH M7**, by the more specific term **mutagenicity** that relates specifically to **DNA mutation**.

OECD 471: Bacterial Reverse Mutation Test (AMES)





KEY ENDPOINTS: GENOTOXICITY



"Gold Standard" for evaluating gene mutations: AMES assay


- protocol using 5 bacterial strains used (Salmonella)
- detect a variety of mutation events
- each strain contains a different combination of genetic modifications (histidine dependent – repair mechanism knocked out)

→ maximize the likelihood that test article induced genetic damage will be expressed as a mutation

- top dose = 5000 µg/plate for soluble, non-toxic test articles
- Impurities: 250 µg/plate (85% of mutagens are detected)
- incubations carried out with and without exogenous source of metabolic activation

KEY ENDPOINTS: GENOTOXICITY







Skin irritation and skin corrosion refer to localized toxic effects resulting from a topical exposure of the skin to a substance.

Skin <u>irritation</u> is "the production of <u>reversible damage</u> to the skin following the application of a test substance for up to 4 hours (i.e. rash development).

Skin <u>corrosion</u> is "the production of <u>irreversible damage</u> to the skin; namely, visible **necrosis** through the epidermis and into the dermis, following the application of a test substance for up to 4 hours.

OECD 404 Skin Irritation Test:

0,5g or 0,5 mL of pure substance is applied to the shaved skin of a rabbit, site of application is scored after 14 days of observation.



A *skin sensitizer* is "a substance that will induce an **allergic response following (repeat) skin contact**".

A substance is classified as a **skin sensitizer** when human data show it can **induce a sensitization response** following skin contact *"in a substantial number of persons"* or when *"there are positive results from an appropriate animal test".*

• Allergic Responses: Often Dose Independent!!

OECD 429 Local Lymphnode Assay (LLNA)

Source: alttox.org




Sensitization testing OECD No. 429/442A or B: Local lymph node test (LLNA) - *in vivo* General test principle: Medscape® www.

Min. 4 female mice/group Repeated exposure on the ears (day 1, 2, 3) IV dosing of a radio-active (or other) label (day 6)

Observations

Collection of the auricular lymph nodes (5h later) Stimulation Index (SI) versus control (\geq 3 = positive) EC3 value = % at which SI = 3





Reproductive toxicity includes the toxic effects of a substance on the reproductive ability of an organism and the development of its offspring (teratogenicity).

Reproductive toxicity is defined as "adverse effects [of chemicals] on sexual function and <u>fertility</u> in adult males and females, as well as <u>developmental</u> toxicity to the <u>offspring during pregnancy</u>".

Developmental toxicity considers "adverse effects induced during **pregnancy**, or as a result of **parental exposure** (i.e. via breast feeding)...manifested at any point in the life span of the organism".

Source: alttox.org



The term *carcinogen* denotes a chemical substance or a mixture of chemical substances which **induce cancer** or **increase its incidence**".


An alternate definition is that *carcinogenic substances* are ones that "induce tumors (benign or malignant), increase their incidence or malignancy, or shorten the time to tumor occurrence when they are inhaled, injected, dermally applied, or ingested

Carcinogens are classified according to their mode of action as *genotoxic* (directly altering the genetic material) or *non-genotoxic* (secondary mechanism not related to direct gene damage).

1-2Y Carcinogenicity study: determine Toxic Dose 50% or TD50 at which exposure 50% of the test animals develop tumors.



SOURCES OF TOXICOGICAL DATA



http://toxnet.nlm.nih.gov http://echa.europa.eu/ http://www.epa.gov/hpvis/ http://webnet.oecd.org/hpv/ http://www.inchem.org/ http://ntpapps.niehs.nih.gov/ntp_tox/index.cfm

Training Course Outline

- Basic Toxicological Principles
- Key Toxicological Endpoints
- Applicable Safety Limits and Thresholds
- General Impurity Qualification
- Best Practice Conclusions






Impurity Qualification: The process of acquiring & evaluating date that establishes the biological safety of an individual impurity given impurity profile at the level(s) specified.

- Before drug products go into clinical trials the impurities FOR be qualified in preclinical studies.
 - Typically includes a 14 -28 day study in religion
- Qualification of Impurities in AND Con Q3A (API) & ICH Q3B (drug product)
 - Process describer 3 Jugh Decision tree
 - Defines the CH CH Chang, identification & qualification of impurities for Marketing Authorisation Application
 - E.g. For a drug dosed at up to 2g/day, the threshold for qualification for impurities is 0.15% or 1.0mg/day, whichever is lower

ICH DECISION TREE FOR QUALIFICATION STUDIES





MUTAGENIC IMPURITIES – ICH M7



Assessment & Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk

- **Mutagenicity** Production of transmissible genetic alterations from cell to cell or generation to generation
- The concern is that mutagens can lead to cancer.

PURPOSE:

Provide a framework for

- Identification
- Categorization
- Quantification
- Control
- ... of mutagenic impurities to limit potential carcinogenic risk

Establish levels of Mutagenic Impurities that are expected to pose negligible Carcinogenic Risk.




ICH M7: DNA REACTIVE IMPURITIES

KEY PRINCIPLES:

Limits are predicated on the basis of the Threshold of Toxicological Concern (TTC)

TTC based on analysis of <u>730</u> <u>carcinogens</u> (genotoxic and nongenotoxic), using linear extrapolation from animal onco data; estimates daily exposure to <u>1.5 µg/day</u> for most (genotoxic) carcinogens not likely to exceed lifetime cancer risk of 1 in 10^5 – risk considered acceptable for pharmaceuticals as drugs have a benefit, not normally used for lifetime and precedent of benzene in Q3C.



1,5 mg/kg/day (safe dose for all carc.) x 50 kg BW = 75 mg/day (TD50 value) $\frac{1}{2}$ chance \rightarrow 1 in 100,000 = 75 mg/day / 50,000 \rightarrow 1,5 µg/day

PQRI / ICH M7 THRESHOLD APPROACH



SAFETY CONCERN THRESHOLD (SCT) "Threshold below which a leachable would have a dose

"Threshold below which a leachable would have a dose so low as to present <u>negligible safety concerns</u> from <u>carcinogenic</u> and non-carcinogenic toxic effects"

PQRI for PODP

FDA Qualification Threshold even for acute administration

Tox Endpoint	Others	Sensitizer & Irritant	Carcinogen
Class	Class I	Class II	Class III
Threshold Level (µg/day)	50	5	1.5

THRESHOLD OF TOXICOLOGICAL CONCERN (TTC)

"Threshold of Toxicological Concern (TTC) concept was developed to define an acceptable intake for any unstudied chemical that poses a <u>negligible risk of carcinogenicity</u> or other toxic effects"

ICH M7 guideline

Duration of treatment	≤1 month	>1 -12 months	>1 -10 years	>10 years
Daily intake (µg/day)	120	20	10	1.5





Haber's Rule

$$C x t = k$$

With C = Concentrationt = timek = constant

This means that the <u>toxic effect</u> e.g. stays the same when concentration is doubled in half of the time of exposure

IMPORTANT, because this is the basis for the <u>Staged Approach</u>, suggested in <u>ICH M7</u>

ICH M7 AND THE STAGED TTC

1 day

10000

1000

100

10

on treatment days

given

Dose[µg/person/day]

38250 μg

SF: 300-10x

120 µg

Proposed acceptable dose

10

SF: "Safety Factor" (difference (max./min.) between

30

calculated and proposed doses

100

365

Number of treatment days

1000



Table 2:	Acceptable	Intakes fo	or an l	Individual	Impurity
----------	------------	------------	---------	------------	----------

Duration				>10
of	<u><</u> 1	>1 - 12	>1 - 10	years to
treatment	month	months	years	lifetime
Daily				
intake	120	20	10	1.5
[µg/day]				

Calculated dose corresp. to 10⁻⁵ cancer risk Calculated dose corresp. to 10

SF: 7-1x

3650

1,5 µg

25500

Uniformly distributed over total Number of exposure days

HABER's RULE:

$$C_1 t_1 = C_2 t_2$$

Acceptable cumulative daily dose:

1,5µg/day x 25.550 days = 38,3 mg x 1 day



Accep	Staged Approach as					
Toxicological	Duration of	ration of Therapy		described in ICH M7		
Endpoint	≤ 1 month 1 – 12 months		1 – 10 years > 10 year		's	
Mutagenicity, TTC (SCT)	120	20	10	1.5		
Sensitization – irritation ¹	5	5	5	5		
General ¹ , QT	50	50	50	50		
	atments: Q.T. = 1,5 μ atments: Q.T. = 5 μg make the link t on Threshold (C chables, a scre	ug/day /day o the toxicology (QT) becomes an l o	(mutagenic carcindentification Th	nogen or reshold!	Will be changed in final PQRI PDP document to 5 µg/day	

The threshold approach – AET



<u>ANALYTICAL EVALUATION THRESHOLD</u> (AET)

→ Translating the SCT into Analytical Thresholds for Extractables studies



AET
$$\left(\frac{\mu g}{test \; item}\right) = \frac{\text{SCT}\left(\frac{\mu g}{day}\right)}{\text{number of doses/day}} \ge \frac{\text{number of doses}}{\text{test item}}$$

➔ Screening methods are semi-quantitative: correction factor of 50%

Final AET =
$$\frac{AET}{2}$$

Cornerstone of all E&L testing:

Compounds detected below the (Final) AET are considered to be toxicologically safe and should not be considered for toxicological assessment

34



Calculation AET – example 1 (small volume parenteral)

- Vial with rubber stopper
- Filling volume : 1 mL
- Maximum daily intake: 1 vial/day or 1 mL/day
- $\circ~$ Final AET based on SCT for PDPs?

$$AET = \frac{\text{threshold}}{\text{dose/day}} \times \frac{\text{total # doses}}{\text{test item}}$$
$$= \frac{1.5 \,\mu\text{g/day}}{1 \,\text{dose/day}} \times \frac{1 \,\text{dose}}{\text{test item}}$$
$$= 1.5 \,\mu\text{g/test item}$$

Final AET =
$$\frac{1.5 \frac{\mu g}{test \, item}}{2}$$
 = 0.75 µg/test item

50% uncertainty for screening methods

35

35

Training Course Outline

- Basic Toxicological Principles
- Key Toxicological Endpoints
- Applicable Safety Limits and Thresholds
- General Impurity Qualification
- Best Practice Conclusions



General Impurity Qualification



GENERAL FRAMEWORK

• Exposure assessment

- Concentration of stopper in solvents / drug product
- Dosing volume: 500 mL/d (10 bottles of 50 mL \rightarrow 10 stoppers)
- Frequency of Dosing: Less-then-lifetime, staged TTC
- Route of Exposure

Hazard assessement

- Literature search
 - Classifications
 - Experimental Data
- Prediction methods
 - DEREK
 - CASE Ultra
- Risk assessement
 - > Thresholds
 - TTC (lifetime, staged, less-than-lifetime) or TD50 \rightarrow 1:100,000 risk
 - PQRI limits (have overruled Cramer limits)
 - PDE calculation (or ADI/RfD...)
 - Safety margin
 - Calculation
 - Conclusion



Prediction methods

• (Q)SAR systems:


DEREK = Deductive Estimation of Risk from Existing Knowlegde


- Enpoints selected: bacterial mutagenicity (5 strains)
- Reporting:
 - Alerts found: e.g. : 352 Aromatic amine or amide
 - **Reasoning:** e.g. Mutagenicity is PLAUSIBLE / PROBABLE ...

➤ Multicase (CASE Ultra) → "toxicophores"

- Enpoint selected: mutagenicity (5 strains)
- Reporting:
 - Alerts found: NEGATIVE or POSITIVE / DEACTIVATING e.g.: Alert ID 49: cH:c (-C3H2):c
 - Probability : < 40 (negative); 40-60 (inconclusive); >60 (positive)
- Leadscope, Sarah, ToxTree, OECD Toolbox, ...







General Impurity Qualification



[n.n.]	$C_{13}H_{23}Br$	259.23	
	Evaluation:		
 Ca Ca Ch Ch Ch Infi Infi Infi Infi 	rcinogenicity in human is rcinogenicity in mammal romosome damage in vitr romosome damage in vitr romosome damage in vitr itation (of the eye) in hum itation (of the eye) in man itation (of the respiratory	summary and alerts found): PLAUSIBLE; Alkylating agent is PLAUSIBLE; Alkylating agent o in human is PLAUSIBLE; Alkylating agent o in mammal is PLAUSIBLE; Alkylating agent an is PLAUSIBLE; Allyl halide mal is PLAUSIBLE; Allyl halide tract) in human is PLAUSIBLE; Allyl halide tract) in human is PLAUSIBLE; Allyl halide	ent
 Irri Irri Mu Ra Ra Sk 	tation (of the skin) in hun tation (of the skin) in man tagenicity in vitro in back pid prototypes: nephrotox pid prototypes: nephrotox in sensitisation in human	tract) in mammal is PLAUSIBLE; Allyl halid nan is PLAUSIBLE; Allyl halide nmal is PLAUSIBLE; Allyl halide terium is PLAUSIBLE; Allyl halide; Alkylatir ticity in human is EQUIVOCAL; 1,1-Dimethy ticity in mammal is EQUIVOCAL; 1,1-Dimet is PLAUSIBLE; Haloalkane 1 is PLAUSIBLE; Haloalkane	ng agent ylcyclohexane
	Classification: (Class III	

39



• Impurity Harard Categorization

ICH M7 Class	Description	
Class 1	Known mutagenic carcinogen	Experimental
Class 2	Known mutagen	data
Class 3	Structural alert No Ames test data	
Class 4	Alerting structure; similarity to Ames negative compound	In silico = (Q)SAR assessment
Class 5	No structural alert or alerting structure with negative Ames test	



Class	Definition	Proposed action for control (details in Section 7 and 8)	
1	Known mutagenic carcinogens	Control at or below compound- specific acceptable limit	based on TD ₅₀
2	Known mutagens with unknown carcinogenic potential (bacterial mutagenicity positive*, no rodent carcinogenicity data)	Control at or below acceptable limits (appropriate TTC)	based on TTC:
3	Alerting structure, unrelated to the structure of the drug substance; no mutagenicity data	Control at or below acceptable limits (appropriate TTC) or conduct bacterial mutagenicity assay; If non-mutagenic = Class 5 If mutagenic = Class 2	lifetime / staged - less-than-lifetime
4	Alerting structure, same alert in drug substance or compounds related to the drug substance (e.g., process intermediates) which have been tested and are non-mutagenic	Treat as non-mutagenic impurity	Higher threshold: predefined limits based on NOAEL
5	No structural alerts, or alerting structure with sufficient data to demonstrate lack of mutagenicity or carcinogenicity	Treat as non-mutagenic impurity	or QT (no data) or Read-Across



So, we have a positive prediction we cannot invalidate ? What Do We Do?



ICH M7	Description		
Class	•	Control at or below TTC (e.g. 1,5 µg/day)	
Class 1	Known mutagenic carcinogen	Experimental	
Class 2	Known mutagen	data	
Class 3	Structural alert No Ames test data	Perform AMES	
Class 4	Alerting structure; similarity to Ames negative compound	In silico assessment	
Class 5	No structural alert or alerting structure with negative Ames test	PDE calculation	

ICH Q3C(R6): RESIDUAL SOLVENTS



Deriving Permissible Daily Exposure (PDEs) for Impurities

 $PDE = \frac{\text{NO(A)EL x Weight Adjustment}}{F1 \text{ x F2 x F3 x F4 x F5}}$

F1 = Variation between Species

F2 = for Variation between individual Humans

F3 = Short Duration in Animals to Chronical Human Exposure

F4 = Teratogenicity, Neurotoxicity and non-genotoxic carcinogens

F5 = 10 for using <u>L</u>OAEL


Sometimes **F6:** route of administration: factor 10 from oral to I.V.

REMARK: NEVER USE LD50 TO CALCULATE A PDE!

IF LD50 IS THE ONLY TOX INFORMATION, ADD LARGE ADDITIONAL SAFETY MARGINS! Literature mentions Safety factors for LD50 as high as 2000 to obtain a NOAEL







Training Course Outline

- Basic Toxicological Principles
- Key Toxicological Endpoints
- Applicable Safety Limits and Thresholds
- General Impurity Qualification
- Best Practice Conclusions



BEST PRACTICE CONCLUSIONS



- Safety principles underpinned by Paracelsian principle poison is in the dose.
- NOAEL/NOEL Levels in Systemic Toxicity testing allow to calculate PDE levels when not:
 - Mutagenic carcinogenic
 - Sensitizing or irritating
- Conservative approach taken for Mutagenic Impurities
 - Use of Linear extrapolation to 1 in 100,000 risk, used to establish TTC lifetime limit of 1.5 µg/day.
 - Staged TTC Approach (based upon Haber's Rule) can be used where the identified compound is identified to be a potential carcinogen, mutagen or genotoxic compound (and compound is not sensitizer/irritant)
 - This concept CANNOT be used as an IDENTIFICATION THRESHOLD in Extractables & Leachables (concern for sensitizers)

BEST PRACTICE CONCLUSIONS



- Conservative approach taken for Mutagenic Impurities
 - If a compound has Actual Toxicity Data on Carcinogenicity/Mutagenicity, USE AVAILABLE DATA, instead of generic approach
 - Often, this will allow you to increase the level of concern for the compound.
- <u>Final Toxicological Assessment</u> needs to be done <u>on the "quantitative" Leachable</u> <u>results</u>
- Leave toxicology to toxicologists; all assessments must be <u>verified by a certified</u> <u>Toxicologist.</u>